China SXT Pharmaceuticals (SXTC) Other Gross PP&E Adjustments (2018 - 2025)
China SXT Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 8 years, most recently at $2.2 million for Q1 2025.
- For Q1 2025, Other Gross PP&E Adjustments fell 1.12% year-over-year to $2.2 million; the TTM value through Mar 2025 reached $2.2 million, down 1.12%, while the annual FY2025 figure was $2.2 million, 1.12% down from the prior year.
- Other Gross PP&E Adjustments for Q1 2025 was $2.2 million at China SXT Pharmaceuticals, down from $2.3 million in the prior quarter.
- Over five years, Other Gross PP&E Adjustments peaked at $2.7 million in Q1 2022 and troughed at -$358569.0 in Q3 2021.
- A 5-year average of $1.6 million and a median of $2.2 million in 2025 define the central range for Other Gross PP&E Adjustments.
- Biggest five-year swings in Other Gross PP&E Adjustments: tumbled 413.75% in 2021 and later grew 18.65% in 2024.
- Year by year, Other Gross PP&E Adjustments stood at -$358569.0 in 2021, then increased by 4.3% to -$343153.0 in 2022, then surged by 654.45% to $1.9 million in 2023, then grew by 18.65% to $2.3 million in 2024, then decreased by 1.12% to $2.2 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for SXTC at $2.2 million in Q1 2025, $2.3 million in Q1 2024, and $1.9 million in Q1 2023.